

31 March 2023

Tender results

Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2022/23 Invitation to Tender, dated 31 October 2022.

Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceuticals under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:

- **For new listings**, by 4pm on the 12th of April 2023 or the 5th of the month prior to listing, whichever is earlier
- **For price changes**, by 4pm on the 12th of the month prior to the date of subsidy change

Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website – <https://pharmac.govt.nz/medicine-funding-and-supply/make-an-application/pharmconnect-make-a-medicine-funding-application/process-for-notification-of-product-changes/>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<http://www.pgnz.org.nz/about-us-1/Pharmacode>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode.

2022/23 Tender – Principal Supply Status applies until 30 June 2026

Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule

The decisions were as follows:

1. Tenders awarded to currently listed Pharmaceuticals where no other brand is listed.

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date
Naltrexone hydrochloride ¹	Tab 50 mg; 30 tablet blister pack	\$133.33	\$83.33	Naltraccord (Teva)	1 July 2023	1 December 2023

¹This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 4 clause 2.3(c)(ii) of the 2022/23 Invitation To Tender.

2. Tenders awarded to pharmaceuticals where at least one other brand is listed

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Listing date	Principal Supply date	Brand (Supplier) affected by delisting
Entecavir	Tab 0.5 mg; 30 tablet blister pack	\$52.00	\$12.04	Entecavir (Rex) (Rex Medical)	1 October 2023	1 March 2024	Entecavir Sandoz (Sandoz) Entecavir Mylan (Viatris)
Ezetimibe	Tab 10 mg; 30 tablet bottle pack	\$1.95	\$1.76	Ezetimibe Sandoz (Sandoz)	1 July 2023	1 December 2023	Ezetimibe Sandoz (Sandoz) Pharmacode 2545861
Hyoscine butylbromide	Inj 20 mg, 1 ml ampoule; 5 ampoule pack	\$6.35	\$1.91	Spazmol (Devatis)	1 July 2023	1 December 2023	Buscopan (Sanofi-Aventi) Buscopan S29 (Sanofi-Aventi)

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Listing date	Principal Supply date	Brand (Supplier) affected by delisting
Ondansetron	Tab disp 4 mg; 10 tablet blister pack	\$0.76	\$0.56	Periset ODT (Miro)	1 October 2023	1 March 2024	Ondansetron ODT- DRLA (Dr Reddy's)
Ondansetron	Tab disp 8 mg; 10 tablet blister pack	\$1.13	\$0.90	Periset ODT (Miro)	1 October 2023	1 March 2024	Ondansetron ODT- DRLA (Dr Reddy's)
Rosuvastatin	Tab 5 mg; 30 tablet bottle pack	\$1.70	\$1.29	Rosuvastatin Viatris (Viatris)	1 July 2023	1 December 2023	Rosuvastatin Viatris (Viatris) Pharmacode 2616742
Rosuvastatin	Tab 10 mg; 30 tablet bottle pack	\$2.42	\$1.69	Rosuvastatin Viatris (Viatris)	1 July 2023	1 December 2023	Rosuvastatin Viatris (Viatris) Pharmacode 2616750
Rosuvastatin	Tab 20 mg; 30 tablet bottle pack	\$3.92	\$2.71	Rosuvastatin Viatris (Viatris)	1 July 2023	1 December 2023	Rosuvastatin Viatris (Viatris) Pharmacode 2616769
Rosuvastatin	Tab 40 mg; 30 tablet bottle pack	\$5.28	\$4.55	Rosuvastatin Viatris (Viatris)	1 July 2023	1 December 2023	Rosuvastatin Viatris (Viatris) Pharmacode 2616777

Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.

3. Tenders awarded to Pharmaceuticals where no other brand is listed.

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV limit	Date of price change	Principal Supply date
Docetaxel ²	Inj 10 mg per ml, 8 ml vial; 1 vial pack	\$46.89	\$24.91	DBL Docetaxel (Pfizer)	5%	1 July 2023	1 December 2023
Melphalan ³	Inj 50 mg vial; 1 vial pack	\$65.00	\$48.25	Melpha (Luminarie)	5%	1 July 2023	1 December 2023
Naltrexone hydrochloride ⁴	Tab 50 mg; 30 tablet blister pack	\$133.33	\$83.33	Naltracord (Teva)	5%	1 July 2023	1 December 2023

²The price and subsidy of docetaxel (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 July 2023. The subsidy of docetaxel (Baxter) inj will also be amended from \$0.65 per 1 mg to \$0.35 mg per 1 mg from 1 July 2023

³The price and subsidy of melphalan (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 July 2023.

⁴This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 4, clause 2.3 (c)(ii) of the 2022/23 Invitation To Tender.

4. Tenders awarded to pharmaceuticals where at least one other brand is listed.

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV limit	Listing date	Principal Supply date	Brand (Supplier) affected by delisting
Entecavir	Tab 0.5 mg; 30 tablet blister pack	\$52.00	\$12.04	Entecavir (Rex) (Rex Medical)	5%	1 October 2023	1 March 2024	Entecavir Sandoz (Sandoz)
Ezetimibe	Tab 10 mg; 30 tablet bottle pack	\$1.95	\$1.76	Ezetimibe Sandoz (Sandoz)	5%	1 July 2023	1 December 2023	Ezetimibe Sandoz (Sandoz) Pharmacode 2545861
Hyoscine butylbromide	Inj 20 mg, 1 ml ampoule; 5 ampoule pack	\$6.35	\$1.91	Spazmol (Devatis)	5%	1 July 2023	1 December 2023	Buscopan (Sanofi- Aventi)

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV limit	Listing date	Principal Supply date	Brand (Supplier) affected by delisting
Ondansetron	Tab dispersible 4 mg; 10 tablet blister pack	\$0.76	\$0.56	Periset ODT (Miro)	5%	1 October 2023	1 March 2024	Ondansetron ODT- DRLA (Dr Reddy's)
Ondansetron	Tab dispersible 8 mg; 10 tablet blister pack	\$1.13	\$0.90	Periset ODT (Miro)	5%	1 October 2023	1 March 2024	Ondansetron ODT- DRLA (Dr Reddy's)
Rosuvastatin	Tab 5 mg; 30 tablet bottle pack	\$1.70	\$1.29	Rosuvastatin Viatris (Viatris)	5%	1 July 2023	1 December 2023	Rosuvastatin Viatris (Viatris) Pharmacode 2616742
Rosuvastatin	Tab 10 mg; 30 tablet bottle pack	\$2.42	\$1.69	Rosuvastatin Viatris (Viatris)	5%	1 July 2023	1 December 2023	Rosuvastatin Viatris (Viatris) Pharmacode 2616750
Rosuvastatin	Tab 20 mg; 30 tablet bottle pack	\$3.92	\$2.71	Rosuvastatin Viatris (Viatris)	5%	1 July 2023	1 December 2023	Rosuvastatin Viatris (Viatris) Pharmacode 2616769
Rosuvastatin	Tab 40 mg; 30 tablet bottle pack	\$5.28	\$4.55	Rosuvastatin Viatris (Viatris)	5%	1 July 2023	1 December 2023	Rosuvastatin Viatris (Viatris) Pharmacode 2616777

Tender declines - Products where no tender is to be awarded for Principal Supply Status

Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2022/23 Invitation to Tender, dated 31 October 2022.

Chemical name	Line item
Ezetimibe (Widened access)	Tab 10 mg
Capsaicin	Crn 0.025%
Capsaicin (Current access)	Crn 0.075%
Capsaicin (Widened access)	Crn 0.075%
Metyrapone	Cap 250 mg
Rifaximin	Tab 200 mg – 550 mg
Vecuronium	Inj 10 mg

For products included in the 2020/21, 2021/22 and 2022/2023 Invitation to Tender where no announcement has yet been made, either a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.